Literature DB >> 2577282

Drugs interacting with alpha adrenoceptors.

P A van Zwieten1.   

Abstract

Alpha adrenoceptors should be divided into various subtypes, comprising pre/postsynaptic and alpha 1/alpha 2-subpopulations, respectively. This classification implicates important functional differences between the various alpha-receptor subtypes, including certain differences in signal transduction following receptor stimulation. After a brief synopsis of the modern classification of alpha-adrenoceptors and its functional implications, the emphasis of the present survey is laid upon the various drugs that interact with the different alpha-adrenoceptor subtypes. Accordingly, agonists and antagonists towards alpha 1- and alpha 2-adrenoceptors are discussed with respect to the pharmacologic basis of their therapeutic activity. Some attention is paid to alpha 1-adrenoceptor antagonists with additional pharmacological activities, e.g., labetalol, ketanserin, and urapidil. Finally, the indirect and rather subtle interaction of calcium antagonists and ACE inhibitors with alpha-adrenoceptor-triggered vasoconstriction is also dealt with, in particular with respect to the influence of these drugs on receptor-operated calcium channels and signal transduction following receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577282     DOI: 10.1007/bf01883855

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  47 in total

1.  Indoramin and prazosin as adjuncts to beta adrenoceptor blockade in hypertension.

Authors:  G S Stokes; G W Frost; R M Graham; E P MacCarthy
Journal:  Clin Pharmacol Ther       Date:  1979-06       Impact factor: 6.875

2.  Central hypotensive activity of ketanserin in cats.

Authors:  P A van Zwieten; M J Mathy; H W Boddeke; H N Doods
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

3.  The central hypotensive effect of clonidine. Studies in tetraplegic subjects.

Authors:  J L Reid; L M Wing; C J Mathias; H L Frankel; E Neill
Journal:  Clin Pharmacol Ther       Date:  1977-04       Impact factor: 6.875

4.  Role of alpha 1- and alpha 2-adrenoceptors in the modulation of the baroreflex vagal bradycardia.

Authors:  A M Huchet; J Chelly; H Schmitt
Journal:  Eur J Pharmacol       Date:  1981-05-22       Impact factor: 4.432

5.  The effect of clonidine on centrally and peripherally evoked submaxillary salivation.

Authors:  G J Green; H Wilson; M S Yates
Journal:  Eur J Pharmacol       Date:  1979-01-15       Impact factor: 4.432

6.  Influence of captopril and enalapril on regional vascular alpha-adrenergic receptor reactivity in SHR.

Authors:  C Richer; M P Doussau; J F Giudicelli
Journal:  Hypertension       Date:  1984 Sep-Oct       Impact factor: 10.190

7.  Vascular alpha-adrenoceptors in man: interactions with adrenaline and noradrenaline.

Authors:  P van Brummelen; K Jie; P Vermey; P B Timmermans; P A van Zwieten
Journal:  Clin Sci (Lond)       Date:  1985       Impact factor: 6.124

8.  Characterization of the antihypertensive activity of SK&F 86466, a selective alpha-2 antagonist, in the rat.

Authors:  J M Roesler; J P McCafferty; R M DeMarinis; W D Matthews; J P Hieble
Journal:  J Pharmacol Exp Ther       Date:  1986-01       Impact factor: 4.030

9.  Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites.

Authors:  G Gross; G Hanft; N Kolassa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-12       Impact factor: 3.000

10.  Pharmacology of terazosin.

Authors:  J J Kyncl
Journal:  Am J Med       Date:  1986-05-23       Impact factor: 4.965

View more
  1 in total

Review 1.  Modulation of sympathetic outflow by centrally acting antihypertensive drugs.

Authors:  P A van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.